Known targets — ChEMBL curated mechanism
GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3B
The experimentally established mechanism targets of Memantine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 known ✓ | Q05586 | 10/20 | 0.95 |
| ▸ | GRIN2A known ✓ | Q12879 | 10/20 | 0.95 |
| ▸ | GRIN2D known ✓ | O15399 | 9/20 | 0.95 |
| ▸ | GRIN3B known ✓ | O60391 | 9/20 | 0.95 |
| ▸ | GRIN2B known ✓ | Q13224 | 9/20 | 0.95 |
| ▸ | GRIN2C known ✓ | Q14957 | 9/20 | 0.95 |
| ▸ | GRIN3A known ✓ | Q8TCU5 | 9/20 | 0.95 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.95 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.95 |
| ▸ | HTT | P42858 | 2/20 | 0.95 |
| ▸ | ESR1 | P03372 | 1/20 | 0.95 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.95 |
| ▸ | ACHE | P22303 | 1/20 | 0.95 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.95 |
| ▸ | MTOR | P42345 | 1/20 | 0.95 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.95 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.95 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Memantine SCHEMBL5011429 | 0.98 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL8126868 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2688 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL12959066 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL13198606 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL23327176 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL2689 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL5606188 | 0.97 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL6368832 | 0.95 | GRIN1 (1.00) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| Memantine SCHEMBL25223076 | 0.95 | GRIN1 (0.95) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894023-B2 | Oral pH independent dosage formulation for treating neurodegenerative disorders | CENTER LABORATORIES, INC. (TW) | 2021-01-19 | — | — | US | disclosed |
| US-8815288-B2 | Oral dosage formulation containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders | CENTER LABORATORIES, INC. (TW) | 2014-08-26 | — | — | US | disclosed |
| US-8802143-B2 | Method for treating neurodegenerative disorders with oral dosage formulation containing both immediate-release and sustained-release drugs | CENTER LABORATORIES, INC. (TW) | 2014-08-12 | — | — | US | disclosed |
| WO-2012129759-A1 | ORAL DOSAGE FORMULATIONS CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS FOR TREATING NEURODEGENERATIVE DISORDERS | CENTER LABORATORIES, INC. (CN) | 2012-10-04 | — | — | WO | disclosed |
| US-20120177735-A1 | ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS FOR TREATING NEURODEGENERATIVE DISORDERS | CENTER LABORATORIES, INC. (TW) | 2012-07-12 | — | — | US | disclosed |
| US-20110171302-A1 | METHOD FOR TREATING NEURODEGENERATIVE DISORDERS WITH ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS | CENTER LABORATORIES, INC. (TW) | 2011-07-14 | — | — | US | disclosed |
| WO-2011038574-A1 | ORAL DOSAGE FORMULATION CONTAINING BOTH IMMEDIATE-RELEASE AND SUSTAINED-RELEASE DRUGS FOR TREATING NEURODEGENERATIVE DISORDERS | CENTER LABORATORIES, INC. (CN) | 2011-04-07 | — | — | WO | disclosed |
| CN-101102994-A | Polymorphs of memantine hydrochloride | TEVA PHARM FINE CHEMICALS SRL (IT) | 2008-01-09 | — | — | CN | disclosed |